The U.S. Food and Drug Administration on April 21, 2026, approved Merck’s Idvynso, a once-daily combination pill for HIV ...

Idvynso uniquely offers a two-drug, tenofovir-free, non-INSTI single-tablet regimen intended for switch in stable, suppressed ...

Islatravir-doravirine matched alternate regimens in two phase III trials ...

Idvynso is a new once-daily, two-drug oral regimen for adults with HIV-1 who are virologically suppressed and have no history ...

Merck is carving out its own place in the evolving HIV treatment space with an FDA approval for its Idvynso, a combination ...

FDA approves doravirine/islatravir, a once-daily, 2-drug, single-tablet HIV regimen showing noninferior efficacy to standard ...

Merck’s Idvynso, a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir gets US FDA approval for the treatment of HIV-1 infection: Rahway, New Jersey ...

Aedes aegypti, commonly known as the yellow fever mosquito, is a highly adapted, invasive mosquito species recognized as a ...

Aedes aegypti, commonly known as the yellow fever mosquito, is a highly adapted, invasive mosquito species recognized as a major global health threat that acts as the primary vector for several severe ...

Boston)—Aedes aegypti, commonly known as the yellow fever mosquito, is a highly adapted, invasive mosquito species recognized as a major global ...

This approval marks an important new chapter in Merck’s long-standing commitment to research and discovery for people living ...

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.